Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System.
Umed A Ajani, Earl S Ford, Kurt J Greenland...
https://pubmed.ncbi.nlm.nih.gov/16414427/Actively Recruiting
Led by Seoul National University Hospital · Updated on 2025-12-31
11086
Participants Needed
61
Research Sites
156 weeks
Total Duration
Researchers are evaluating the effectiveness and safety of clopidogrel for preventing major cardiovascular and cerebrovascular events in patients who have subclinical coronary atherosclerosis detected by imaging but do not need revascularization therapy. This study focuses on primary prevention in these patients, who are at increased risk of heart attacks or cardiac death compared to those without coronary atherosclerosis. The study is a phase 4 interventional trial sponsored by Seoul National University Hospital. Participants will be randomly assigned to one of two groups. One group will take clopidogrel 75mg once daily for at least five years. The other group will not receive any antiplatelet or anticoagulant therapy for at least five years, unless medically needed during follow-up, in which case medication may be prescribed with reporting to the research board. This long-term treatment period aims to assess the prevention of major adverse cardiovascular and cerebrovascular events. During the study, participants will be monitored for major cardiovascular and cerebrovascular events, including heart attacks, strokes, and deaths, at two and five years after the last participant enrolls. Researchers will also track bleeding events and other clinical outcomes. Participants will provide informed consent and undergo assessments related to their cardiovascular health over the course of the study, which continues until the end date in 2031.
CONDITIONS
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)
J
Jung-Kyu Han, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Seoul National University Hospital
Lead Sponsor
Samjin Pharmaceutical Co., Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - At least 5 years
Participants receive clopidogrel 75mg once a day or no antiplatelet therapy for primary prevention of cardiovascular events.
Regular visits for monitoring during treatment
Duration - Up to 5 years after treatment
Participants are monitored for cardiovascular events and safety outcomes after treatment.
Visits at 2 and 5 years after the last enrollment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Umed A Ajani, Earl S Ford, Kurt J Greenland...
https://pubmed.ncbi.nlm.nih.gov/16414427/Bon-Kwon Koo, Jeehoon Kang, Kyung Woo Park...
https://pubmed.ncbi.nlm.nih.gov/34010616/Ali Yazdanyar, Anne B Newman
https://pubmed.ncbi.nlm.nih.gov/19944261/John J McNeil, Rory Wolfe, Robyn L Woods...
https://pubmed.ncbi.nlm.nih.gov/30221597/Clerio F de Azevedo, Marcelo S Hadlich, Sabrina G Bezerra...
https://pubmed.ncbi.nlm.nih.gov/21757164/Sunitha V Ittaman, Jeffrey J VanWormer, Shereif H Rezkalla
https://pubmed.ncbi.nlm.nih.gov/24573704/ASCEND Study Collaborative Group, Louise Bowman, Marion Mafham...
https://pubmed.ncbi.nlm.nih.gov/30146931/Phillip J Habib, Jacinta Green, Ryan C Butterfield...
https://pubmed.ncbi.nlm.nih.gov/24090745/C H Hennekens, M L Dyken, V Fuster
https://pubmed.ncbi.nlm.nih.gov/9355934/Frank L J Visseren, François Mach, Yvo M Smulders...
https://pubmed.ncbi.nlm.nih.gov/34458905/Seoul National University Hospital
Lead Sponsor
Samjin Pharmaceutical Co., Ltd.
Collaborating Sponsor